Become a Member

Track your favourite stocks
Create & monitor portfolios
Daily portfolio value

Company	Chg	Chg %
Quickpicks
£	%
Add shares to your quickpicks to display them here!

Physiomics (PYC) Share Price

Intraday
Historical

Price	0.415p on 02-06-2025 at 17:35:09
Change	0.01p 2.47%
Buy	0.42p
Sell	0.41p
Buy / Sell PYC Shares

Last Trade:	Buy 500,000.00 at 0.4195p
Day's Volume:	7,846,707
Last Close:	0.415p
Open:	0.405p
ISIN:	GB00BDR6W943

Day's Range	0.405p - 0.415p
52wk Range:	0.39p - 1.50p
Market Capitalisation:	£1m
VWAP:	0.407923p
Shares in Issue:	303m

Sector: Medical Services

Listed In: FTSE AIM All-Share,

Buy/Sell	Volume	Trade Prc	Trade Type	Trade Time
Physiomics (PYC) Latest Trades
Buy*	500,000	0.4195p	Ordinary	16:25:13 - 02-Jun-25
Buy*	240	0.4195p	Ordinary	16:03:51 - 02-Jun-25
Buy*	1	0.4195p	Ordinary	16:03:06 - 02-Jun-25
Buy*	1	0.419p	Ordinary	16:02:18 - 02-Jun-25
Buy*	200,000	0.419p	Ordinary	15:47:51 - 02-Jun-25
Buy*	1,200,963	0.416p	Ordinary	15:23:01 - 02-Jun-25
Buy*	328,617	0.416p	Ordinary	15:10:41 - 02-Jun-25
Buy*	1,043,940	0.417p	Ordinary	15:09:29 - 02-Jun-25
Sell*	587,225	0.4015p	Ordinary	13:51:21 - 02-Jun-25
Buy*	303,367	0.416p	Ordinary	13:09:23 - 02-Jun-25

See more Physiomics trades

Physiomics (PYC) Share Price History
Time period: to
Date	Open	High	Low	Close	Volume
30th May 2025 (Fri)	0.415	0.415	0.405	0.405	3,848,958
29th May 2025 (Thu)	0.425	0.425	0.415	0.415	7,222,568
28th May 2025 (Wed)	0.405	0.405	0.405	0.405	1,998,209
27th May 2025 (Tue)	0.42	0.42	0.405	0.405	6,295,747
26th May 2025 (Mon)	0.41	0.41	0.41	0.41	0
23rd May 2025 (Fri)	0.42	0.42	0.42	0.42	2,583,899
22nd May 2025 (Thu)	0.42	0.42	0.42	0.42	909,280
21st May 2025 (Wed)	0.42	0.42	0.42	0.42	1,796,772
20th May 2025 (Tue)	0.42	0.42	0.42	0.42	1,563,056
19th May 2025 (Mon)	0.42	0.42	0.42	0.42	1,305,302
16th May 2025 (Fri)	0.425	0.425	0.42	0.42	2,235,641
15th May 2025 (Thu)	0.425	0.425	0.425	0.425	82,127
14th May 2025 (Wed)	0.43	0.435	0.425	0.425	4,427,257
13th May 2025 (Tue)	0.415	0.43	0.415	0.43	3,629,444
12th May 2025 (Mon)	0.42	0.42	0.415	0.415	1,933,331
9th May 2025 (Fri)	0.455	0.46	0.415	0.42	8,186,194
8th May 2025 (Thu)	0.48	0.48	0.44	0.44	6,850,871
7th May 2025 (Wed)	0.445	0.48	0.445	0.48	8,408,824
6th May 2025 (Tue)	0.42	0.445	0.42	0.445	10,591,417
5th May 2025 (Mon)	0.402	0.402	0.402	0.402	0
2nd May 2025 (Fri)	0.425	0.425	0.42	0.42	2,281,590

See more Physiomics price history

Date	Source	Headline
Physiomics (PYC) Regulatory News
29th May 2025 7:00 am	RNS	Physiomics Awarded Contract Extension
9th May 2025 7:00 am	RNS	Contract Award with New UK Client
7th May 2025 4:45 pm	RNS	AIM Rule 17 and Schedule 2(g) Update
17th Apr 2025 7:00 am	RNS-R	Physiomics Awarded New Contract
16th Apr 2025 7:00 am	RNS-R	Publication of Peer Reviewed Article
15th Apr 2025 7:00 am	RNS-R	Contract Award
17th Mar 2025 7:00 am	RNS	Contract Award with new client
13th Mar 2025 7:00 am	RNS-R	IMC Presentation on Company Website
6th Mar 2025 7:00 am	RNS	Interim Results
28th Feb 2025 7:00 am	RNS	Notice of Results and Investor Presentation

See more Physiomics regulatory news

Physiomics (PYC) Share News

Physiomics wins clinical development contract with new UK client

9th May 2025 13:06

(Alliance News) - Physiomics PLC on Friday said it has won a contract with a new client in the UK. Read More

Physiomics extends long-term collaboration with Numab via new contract

15th Apr 2025 18:23

(Alliance News) - Physiomics PLC on Tuesday said it has secured a new contract with long-standing client Numab Therapeutics AG, a Swiss clinical stage biotech company focused on the development of multi-specific antibodies in immunology and oncology. Read More

IN BRIEF: Physiomics secures GBP102,000 model development contract

17th Mar 2025 16:22

Physiomics PLC - Oxfordshire, England-based mathematical modelling company that supports oncology drug development - Secures contract worth GBP102,000 with a new UK-based biotech firm that is focused on developing antibody drug conjugates based therapies targeting difficult-to-treat cancers. Says the contract will see it develop a pharmacokinetic pharmacodynamic model to inform optimal dosing for the client's upcoming first-in-human trial. Expects the project to run from April until August this year. Chief Executive Peter Sargent says: "We are delighted to be awarded this contract. Not only is this contract with a brand new client, but is also in the area of ADCs; a hot new area of oncology treatments." Read More

IN BRIEF: Physiomics eyes new contracts but half-year loss widens

6th Mar 2025 19:08

Physiomics PLC - Oxfordshire, England-based mathematical modelling company that supports oncology drug development - Pretax loss widens to GBP249,000 in the six months to December 31 compared with GBP235,000 a year prior as revenue dips 12% to GBP329,000 from GBP374,000. Highlights strong pipeline with four contracts won in the first half of the financial year. Based on these signed contracts, the company expects total income for the current financial year will be in line with market expectations, with additional contracted revenue projected into next year - year to June 2026. The company is "actively progressing" a number of late-stage opportunities, however, there is no guarantee that these contracts will be signed within the current financial year. Read More

EARNINGS AND TRADING: Tullow eyes non-core sales; Treatt backs outlook

31st Jan 2025 16:36

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More

See more Physiomics news

FTSE 100 Latest

Value8,774.26

Change1.88

Physiomics (PYC) Share Price

Login to your account